Supernus Pharmaceuticals, Inc. SUPN 深 滬
等待開盤 08-10 09:30:00 美东时间
47.64
+0.880
+1.88%
華盛通- 最 高47.88
- 今 開47.00
- 成交量 70.26万股
- 最 低 46.43
- 昨 收 46.76
- 總市值 27.69亿
- 52周最高 59.68
- 市盈率 靜 --
- 換手率 1.21%
- 52周最低 41.783
- 委 比 -6.13%
- 總股本 5812.70万
- 歷史最高 61.25
- 量 比 0.30
- 振 幅 3.10%
- 歷史最低 4.30
- 每 手 1
- 風險率 3.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Supernus Pharmaceuticals, Inc. 2026财年年度营收8.30亿美元，同比持平；归母净利润0.00亿美元，同比持平
华盛资讯8月4日讯，Supernus Pharmaceuticals, Inc.公布2026财年年度业绩，公司年度营收8.30亿美元，同比持平，归母净利润0.00亿美元，同比持平。
08-04 05:19
财报速睇 | Supernus Pharmaceuticals, Inc. 2026财年Q2营收2.19亿美元，同比增长32.4%；归母净利润亏损0.58亿美元，由盈转亏
华盛资讯8月4日讯，Supernus Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收2.19亿美元，同比增长32.4%，归母净利润亏损0.58亿美元，由盈转亏。
08-04 03:49
财报速睇 | Supernus Pharmaceuticals, Inc. 2026财年Q2营收2.19亿美元，同比增长32.4%；归母净利润亏损0.58亿美元，由盈转亏
华盛资讯8月4日讯，Supernus Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收2.19亿美元，同比增长32.4%，归母净利润亏损0.58亿美元，由盈转亏。
08-04 02:10
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
08-04 01:41
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.42 by 26.19 percent. This is a 32.5 percent increase over earnings of $0.40 per share from the same period last year.
08-03 21:27
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceut...
08-03 18:35
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.
07-09 23:06
电话会总结 ｜ Supernus(SUPN)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Supernus业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收达到2.077亿美元，同比增长39% - 商业产品营收1.78亿美元，同比增长26% - 主要增长驱动来自核心增长品牌和新的合作营收 **盈利能力：** - GAAP营业亏损830万美元，较去年同期1030万美元亏损有所收窄 - Non-GAAP调整后营业利润2870万美元，较去年同期2590万美元增长11% - GAAP净亏损230万美元（每股亏损0.04美元），较去年同期1180万美元净亏损大幅改善 **现金状况：** - 现金、现金等价
05-06 12:28
财报速睇 | Supernus制药 2026财年Q1营收2.08亿美元，同比增长38.7%；归母净利润亏损0.02亿美元，同比亏损缩窄83.3%
华盛资讯5月6日讯，Supernus制药公布2026财年Q1业绩，公司Q1营收2.08亿美元，同比增长38.7%，归母净利润亏损0.02亿美元，同比亏损缩窄83.3%。
05-06 08:07
